
Dr. Rafael Davalos' research interests are in microfluidics for personalized medicine and developing technologies for cancer therapy. He is most recognized for co-inventing Irreversible Electroporation (IRE), a minimally invasive non-thermal surgical technique to treat unresectable tumors near critical structures such as major blood vessels and nerves. The technology has been used to help thousands of patients worldwide with a second-generation version in clinical trials. Davalos has authored 150 peer-reviewed articles and has 47 issued patents (72 h-index, >18,000 citations) and has secured over $37M in research funding with $10M his share. His patents have been licensed to 7 companies. He has been a plenary speaker for several prestigious venues including the International Symposium of the Bioelectrochemistry Society, the World Congress on Electroporation, and the Society of Cryobiology Annual Meeting.